Public Engagement for Regulatory Reform: A Case Study of Autologous Stem Cell Therapy Regulation in Australia

Abstract

As a method of science communication, public consultations have the potential to offer members of society the opportunity to influence government policy. An important component of public consultations is the evaluation of stakeholder submissions (from individuals to large organizations). As a case study, we investigated an Australian public consultation on the regulation of autologous stem cell therapies (ASCT) facilitated by the Therapeutic Goods Administration. Our results showed a divide between stakeholders who wanted ASCT to remain unregulated and stakeholders who wanted ASCT to become regulated. Since the consultation, the Therapeutic Goods Administration has decided to implement stringent regulation of most ASCT.

Keywords

science communication public engagement public consultation autologous stem cell therapy

Get full access to this article

View all access options for this article.

References

Berger

Ahmad

Bansal

Kapoor

Sipp

Rasko

J. E.

(2016). Global distribution of businesses marketing stem cell-based interventions. Cell Stem Cell, 19, 158-162. doi:10.1016/j.stem.2016.07.015

Braun

Clarke

(2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3, 77-101. doi:10.1191/1478088706qp063oa

Brossard

Lewenstein

B. V.

(2010). A critical appraisal of models of public understanding of science: Using practice to inform theory. New York, NY: Routledge.

Bubela

Nisbet

M. C.

Borchelt

Brunger

Critchley

Einsiedel

. . . Caulfield

(2009). Science communication reconsidered. Nature Biotechnology, 27, 514-518. doi:10.1038/nbt0609-514

Cook

P. S.

(2011). What constitutes adequate public consultation? Xenotransplantation proceeds in Australia. Journal of Bioethical Inquiry, 8, 67-70. doi:10.1007/s11673-010-9269-8

Daley

G. Q.

(2012). The promise and perils of stem cell therapeutics. Cell Stem Cell, 10, 740-749. doi:10.1016/j.stem.2012.05.010

Daley

G. Q.

(2017). Polar extremes in the clinical use of stem cells. New England Journal of Medicine, 376, 1075-1077. doi:10.1056/NEJMe1701379

Fereday

Muir-Cochrane

(2006). Demonstrating rigor using thematic analysis: A hybrid approach of inductive and deductive coding and theme development. International Journal of Qualitative Methods, 5, 80-92.

Gerhards

Schäfer

M. S.

(2009). Two normative models of science in the public sphere: Human genome sequencing in German and US mass media. Public Understanding of Science, 18, 437-451. doi:10.1177/0963662507082891

10.

Glicken

(1999). Effective public involvement in public decisions. Science Communication, 20, 298-327.

11.

Goldring

C. E.

Duffy

P. A.

Benvenisty

Andrews

P. W.

Ben-David

Eakins

. . . Park

B. K.

(2011). Assessing the safety of stem cell therapeutics. Cell Stem Cell, 8, 618-628. doi:10.1016/j.stem.2011.05.012

12.

Hanahan

Weinberg

R. A.

(2011). Hallmarks of cancer: The next generation. Cell, 144, 646-674. doi:10.1016/j.cell.2011.02.013

13.

Hsieh

H. F.

Shannon

S. E.

(2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15, 1277-1288. doi:10.1177/1049732305276687

14.

International Association for Public Participation. (2014). IAP2’s public participation spectrum. Retrieved from https://www.iap2.org.au/Tenant/C0000004/00000001/files/IAP2_Public_Participation_Spectrum.pdf

15.

International Society for Stem Cell Research. (n.d.-a). Stem cell facts. Retrieved from http://www.isscr.org/docs/default-source/isscr-publications/stem-cell-facts-brochure92203E27C59B.pdf?sfvrsn=2

16.

International Society for Stem Cell Research. (n.d.-b). Stem cell glossary. Retrieved from http://www.closerlookatstemcells.org/patient-resources/stem-cell-glossary#autologous

17.

International Society for Stem Cell Research. (2018). ISSCR applauds Australia’s move to regulate autologous human cell and tissue products. Retrieved from http://www.isscr.org/professional-resources/news-publicationsss/isscr-news-articles/article-detail/2018/04/26/isscr-applauds-australia-s-move-to-regulate-autologous-human-cell-and-tissue-products

18.

Irwin

(2001). Constructing the scientific citizen: Science and democracy in the biosciences. Public Understanding of Science, 10, 1-18.

19.

Kamenova

(2017). Media portrayal of stem cell research: Towards a normative model for science communication. Asian Bioethics Review, 9, 199-209. doi:10.1007/s41649-017-0026-8

20.

Kuriyan

A. E.

Albini

T. A.

Townsend

J. H.

Rodriguez

Pandya

H. K.

Leonard

R. E.

II . . . Goldberg

J. L.

(2017). Vision loss after intravitreal injection of autologous “stem cells” for AMD. New England Journal of Medicine, 376, 1047-1053. doi:10.1056/NEJMoa1609583

21.

Little

M. T.

Storb

(2002). History of haematopoietic stem-cell transplantation. Nature Reviews Cancer, 2, 231-238. doi:10.1038/nrc748

22.

Lysaght

Lipworth

Hendl

Kerridge

Lee

T. L.

Munsie

. . . Stewart

(2017). The deadly business of an unregulated global stem cell industry. Journal of Medical Ethics, 43, 744-746. doi:10.1136/medethics-2016-104046

23.

Marks

P. W.

Witten

C. M.

Califf

R. M.

(2017). Clarifying stem-cell therapy’s benefits and risks. New England Journal of Medicine, 376, 1007-1009. doi:10.1056/NEJMp1613723

24.

McLean

A. K.

Stewart

Kerridge

(2015). Untested, unproven, and unethical: The promotion and provision of autologous stem cell therapies in Australia. Stem Cell Research & Therapy, 6, 33. doi:10.1186/s13287-015-0047-810.1186/scrt543

25.

Munsie

Hyun

(2014). A question of ethics: Selling autologous stem cell therapies flaunts professional standards. Stem Cell Research, 13(3, Pt. B), 647-653. doi:10.1016/j.scr.2014.04.014

26.

Munsie

Pera

(2014). Regulatory loophole enables unproven autologous cell therapies to thrive in Australia. Stem Cells and Development, 23(Suppl. 1), 34-38. doi:10.1089/scd.2014.0332

27.

National Health and Medical Research Council. (2013). Stem cell treatments: A quick guide for medical practitioners. Retrieved from https://www.msnz.org.nz/wp-content/uploads/2017/08/Stem-Cell-Treatment-Quick-Guide-for-Medical-Practitioners.pdf

28.

Nelkin

(1975). The political impact of technical expertise. Social Studies of Science, 5(1), 35-54.

29.

Osborne

Anderson

Burt

Young

Gerrard

(2016). Australasian College of Sports Physicians position statement: The place of mesenchymal stem/stromal cell therapies in sport and exercise medicine. British Journal of Sports Medicine, 50, 1237-1244. doi:10.1136/bjsports-2015-095711

30.

Phillips

C. V.

Goodman

K. J.

(2004). The missed lessons of Sir Austin Bradford Hill. Epidemiologic Perspectives & Innovations, 1(1), 3. doi:10.1186/1742-5573-1-3

31.

Priest

Goodwin

Dahlstrom

(2018). Ethics and practice in science communication. Chicago, IL: University of Chicago Press.

32.

PytlikZillig

Hutchens

Muhlberger

Gonzalez

Tomkins

(2018). Deliberative public engagement with science: An empirical investigation. Berlin, Germany: Springer International.

33.

Rowe

Frewer

L. J.

(2005). A typology of public engagement mechanisms. Science, Technology, & Human Values, 30, 251-290. doi:10.1177/0162243904271724

34.

Sibbald

Roland

(1998). Understanding controlled trials. Why are randomised controlled trials important? BMJ, 316(7126), 201.

35.

Sunstein

C. R.

(2002). The law of group polarization. Journal of Political Philosophy, 10, 175-195. doi:10.1111/1467-9760.00148

36.

Therapeutic Goods Administration. (2015a). Consultation: Regulation of autologous stem cell therapies. Retrieved from https://www.tga.gov.au/consultation/consultation-regulation-autologous-stem-cell-therapies

37.

Therapeutic Goods Administration. (2015b). Submissions received: Regulation of autologous stem cell therapies. Retrieved from https://www.tga.gov.au/submissions-received-regulation-autologous-stem-cell-therapies

38.

Therapeutic Goods Administration. (2017). Regulation of autologous cell and tissue products: Including so called “autologous stem cell” therapies. Retrieved from https://www.tga.gov.au/media-release/regulation-autologous-cell-and-tissue-products

39.

Therapeutic Goods Administration. (2018). Autologous human cell and tissue products. Retrieved from https://www.tga.gov.au/sites/default/files/autologous-human-cells-and-tissues-products-regulation.pdf

40.

Trickett

A. E.

Wall

D. M.

(2011). Regulation of cellular therapy in Australia. Pathology, 43, 627-634. doi:10.1097/PAT.0b013e32834b3cfa

41.

Trounson

McDonald

(2015). Stem cell therapies in clinical trials: Progress and challenges. Cell Stem Cell, 17, 11-22. doi:10.1016/j.stem.2015.06.007

42.

Turner

Knoepfler

(2016). Selling stem cells in the USA: Assessing the direct-to-consumer industry. Cell Stem Cell, 19, 154-157. doi:10.1016/j.stem.2016.06.007

43.

U.S. Department of Health. (2015). Stakeholder engagement framework. Retrieved from http://www.health.gov.au/internet/main/publishing.nsf/Content/stake-frame

44.

U.S. Food & Drug Administration. (2017). FDA warns about stem cell therapies. Retrieved from https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm286155.htm

45.

Vaismoradi

Turunen

Bondas

(2013). Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study. Nursing & Health Sciences, 15, 398-405. doi:10.1111/nhs.12048